Status | Study |
Withdrawn |
Study Name: Adjunctive Everolimus (RAD 001) Therapy for Epilepsy in Children With Sturge-Weber Syndrome (SWS) Condition: Sturge Weber Syndrome Date: 2013-11-15 Interventions: Drug: Everolimus Afinitor tablets will be administered at a starting dosage of 5 mg/ m2/ day, dosed once |
Recruiting |
Study Name: Evaluation of 68Gallium-DOTATATE PET/CT for Detecting Neuroendocrine Tumors Condition: Neuroendocrine Tumors Von Hippel-Lindau Syndrome Hippel-Li Date: 2013-10-18 Interventions: Drug: 68Gallium DOTATATE Fasti |
Completed |
Study Name: Efficacy and Safety Study of Topical Rapamycin Associated With Pulsed Dye Laser in Patients With Sturge-Weber Syndrome Condition: Sturge- Weber Syndrome Date: 2013-04-18 Interventions: Drug: Drug: Topical Rapamycin After signing this consent f |
Recruiting |
Study Name: Treatment of Port-wine Mark in Sturge-Weber Syndrome Using Topical Timolol Condition: Sturge Weber Syndrome Port-wine Mark Date: 2012-02-11 Interventions: Drug: Timolol 0.5% timolol mal |
Recruiting |
Study Name: National Eye Institute Biorepository for Retinal Diseases Condition: Age-Related Macular Degeneration Diabetic Retinopathy Von Date: 2011-12-17 |
Active, not recruiting |
Study Name: Pazopanib in Von Hippel-Lindau (VHL) Syndrome Condition: Von Hippel-Lindau Syndrome Date: 2011-09-15 Interventions: Drug: Pazopanib 800 mg by mouth once daily for up to six, four week cycles. |
Recruiting |
Study Name: Innovative Approaches to Gauge Progression of Sturge-Weber Syndrome Condition: Sturge-Weber Syndrome Date: 2011-08-29 |
Active, not recruiting |
Study Name: French National Cohort of Children With Port Wine Stain Condition: Port Wine Stain Klippel Trenaunay Syndrome Parkes Weber Sy Date: 2011-05-31 Interventions: Genetic: search for polymorphisms of RASA1 gene Blood sample ( 5 mL) at tne inclusion of the child DNA e |
Completed |
Study Name: Biomarker Development in Sturge-Weber Syndrome Condition: Sturge-Weber Syndrome Date: 2011-04-28 |
Terminated |
Study Name: TKI 258 in Von Hippel-Lindau Syndrome (VHL) Condition: Von Hippel-Lindau Syndrome Date: 2010-12-22 Interventions: Drug: Dovitinib 500 mg (5 capsules) daily by mouth on Days 1-5, 8-12, 15-19, and 22-26 of each 28-day cy |